Acute Amiodarone Hepatotoxicity After Liver Transplantation

A 64-year-old white male with end-stage liver disease, secondary to nonalcoholic steatohepatitis and hepatocellular carcinoma, underwent an orthotopic liver transplant (OLT) from a 21-year-old donation-after-cardiac-death donor. Postoperatively, he had primary nonfunction of the allograft manifested by increased hepatic biochemical markers, acute renal failure, increasing lactate level, increasing coagulopathy, and hemodynamic instability. Two days later, he underwent a second OLT and was started on triple-drug immunosuppression regimen as per institutional protocol consisting of tacrolimus, mycophenolate mofetil, and prednisone. He was also started on posttransplant infectious prophylaxis with valganciclovir, sulfamethoxazole-trimethoprim, and mycamine. One day after his second transplant, he experienced atrial fibrillation as detected by telemetry and confirmed on electrocardiography. Consequently, he was started on intravenous amiodarone with a bolus dose of 150 mg followed by a continuous infusion at a rate of 1 mg/min. Esmolol was added on postoperative day (POD) 5 at a rate of 50 µg/kg/min to control the heart rate.

On POD 7, his liver transaminase levels started to increase (Fig. 1A). Alanine aminotransferase (ALT) values increased from 688 to 2028 U/L, aspartate aminotransferase (AST) from 375 to 932 U/L, alkaline phosphatase from 66 to 104 U/L, and bilirubin (BILI) from 6.5 to 13.4 mg/dL. Doppler ultrasound was performed to exclude hepatic artery thrombosis, which showed a patent hepatic artery, portal vein, and hepatic veins with normal blood flow. Endoscopic retrograde cholangiogram did not show any biliary obstruction. In addition, a liver biopsy was performed, which showed canicularial cholestasis, increased mitotic activity, and numerous apoptotic hepatocytes, especially around the central veins; there were no features of acute cellular rejection (Fig. 1B–D). Considering these findings, a likelihood of a drug-related hepatotoxicity was examined. On reviewing his medications, amiodarone was the only drug that is known to cause hepatotoxicity and was stopped after 11 days of therapy. He was then started on metoprolol 100 mg orally twice daily for atrial fibrillation. After withdrawal of amiodarone, DCP level is significantly correlated with infectious prophylaxis with valganciclovir, sulfamethoxazole-trimethoprim, and mycamine. One day after his second transplant, he experienced atrial fibrillation as detected by telemetry and confirmed on electrocardiography. Consequently, he was started on intravenous amiodarone with a bolus dose of 150 mg followed by a continuous infusion at a rate of 1 mg/min. Esmolol was added on postoperative day (POD) 5 at a rate of 50 µg/kg/min to control the heart rate.

On POD 7, his liver transaminase levels started to increase (Fig. 1A). Alanine aminotransferase (ALT) values increased from 688 to 2028 U/L, aspartate aminotransferase (AST) from 375 to 932 U/L, alkaline phosphatase from 66 to 104 U/L, and bilirubin (BILI) from 6.5 to 13.4 mg/dL. Doppler ultrasound was performed to exclude hepatic artery thrombosis, which showed a patent hepatic artery, portal vein, and hepatic veins with normal blood flow. Endoscopic retrograde cholangiogram did not show any biliary obstruction. In addition, a liver biopsy was performed, which showed canicularial cholestasis, increased mitotic activity, and numerous apoptotic hepatocytes, especially around the central veins; there were no features of acute cellular rejection (Fig. 1B–D). Considering these findings, a likelihood of a drug-related hepatotoxicity was examined. On reviewing his medications, amiodarone was the only drug that is known to cause hepatotoxicity and was stopped after 11 days of therapy. He was then started on metoprolol 100 mg orally twice daily for atrial fibrillation. After withdrawal of amiodarone, DCP level is significantly correlated with
odarone, his liver functions gradually normalized over the next 2 weeks (Fig. 1A). He was discharged on POD 25 having nearly normal hepatic function with ALT 72 U/L, AST 27 U/L, and BILI 2.7 mg/dL. At his most recent follow-up, he is 3.5 months posttransplant; doing well; and has a normal hepatic function with ALT 20 U/L, AST 17 U/L, and BILI 0.8 mg/dL.

**DISCUSSION**

Amiodarone is becoming the drug of choice in the treatment of atrial fibrillation, particularly in the postsurgical setting (1,2). However, it is associated with many adverse effects including hepatotoxicity. Amiodarone-induced hepatotoxicity usually occurs with chronic use of oral amiodarone with a reported incidence of approximately 24% to 26%; this is frequently transient and asymptomatic increase of transaminases, which returns to a normal level after dose reduction or withdrawal (3,4). Symptomatic and potentially fatal liver injury has also been reported during intravenous amiodarone treatment (3–7).

Amiodarone-induced hepatotoxicity has been not described in liver transplantation. Its presentation can mimic the more frequent causes of post-OLT hepatic dysfunction including ischemic-reperfusion hepatic injury, hepatic artery thrombosis, rejection, or biliary obstruction and will lead to diagnostic confusion. Our patient developed signs of acute hepatic injury during intravenous amiodarone treatment within therapeutic dosages, and his liver functions normalized gradually after withdrawal of amiodarone. Considering the prevalence of perioperative cardiac arrhythmias after OLT and use of amiodarone to treat them, it may be prudent to say that amiodarone-induced hepatotoxicity is frequent and remained undiagnosed, most likely because of its short-term use and the fact that hepatotoxicity is reversible.

In conclusion, we recommend that clinicians should anticipate this potential adverse effect of amiodarone and consider in differential diagnosis of he-

![FIGURE 1.](image-url) (A) Hepatic biochemical markers over postoperative days with duration of amiodarone therapy; (upper) alanine aminotransferase (ALT) and aspartate aminotransferase (AST, units per liter); (lower) bilirubin (milligram per deciliter). (B) Portal area with no evidence of rejection; (C) cholestasis (arrow); (D) increased mitoses (upper arrow) and apoptotic bodies (lower arrow).
The authors declare no conflict of interests.

Address correspondence to: Ashokkumar Jain, M.D., F.A.C.S., Division of Abdominal Organ Transplantation, Department of Surgery, Temple University Hospital, 3401 North Broad Street, Parksinon Pavilion, 6th Floor, Suite C640, Philadelphia, PA 19140.

E-mail: ashokkumar.jain@tuhs.temple.edu

Received 10 January 2011.

Accepted 19 January 2011.

Copyright © 2011 by Lippincott Williams & Wilkins

ISSN 0041-1337/11/9108-62
DOI: 10.1097/TP.0b013e3182115bc1

REFERENCES


